1. Prokai L (1998) Peptide drug delivery into the central nervous system. In: EM Jucker (ed): Progress in Drug Research, Vol. 51, Birkhäuser, Basel, 96–131
2. Kawai M, Fukuta N, Ito N, Kagami T, Butsugan Y, Maruyama M, Kudo Y (1990) Preparation and opioid activities of N-methylated analogs of [D-Ala2, Leu5]enkephalin. Int J Pept Prot Res 35: 452–459
3. Witt KA, Slate CA, Egleton RD, Huber JD, Yamamura HI, Hruby VJ, Davis TP (2000) Assessment of stereoselectivity of trimethylphenylalanine analogues of δ-opioid [DPhen(2), D-Pen(5)]-enkephalin. JNeurochem 75: 424–435
4. Weber SJ, Greene DL, Sharma SD, Yamamura HI, Kramer TH, Burks TF, Hruby VJ, Hersh LB, Davis TP (1991) Distribution, and analgesia of [H-3][D-Pen2, D-Pen5]enkephalin, and two halogenated analogs after intravenous administration. J Pharm Exp Ther 259: 1109–1117
5. Gentry CL, Egleton RD, Gillespie T, Abbruscato TJ, Bechowski HB, Hruby VJ, Davis TP (1999) The effect of halogenation on blood-brain barrier permeability of a novel peptide drug peptides. Peptides 20: 1229–1238